Robert M. Plenge
Known title: DirectorCIK: 0001773367
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.
Transaction History
| BMRN | ▲ Buy | Grant | 6,140 | $0 | 9/10/2026 | View on chart |
| BMY | ▲ Buy | Option Exercise | 2,342 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Other | 253 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 927 | $56K | 3/10/2026 | View on chart |
| BMY | ▲ Buy | Option Exercise | 14,052 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Other | 6,900 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 3,172 | $191K | 3/10/2026 | View on chart |
| BMY | ▲ Buy | Option Exercise | 1,107 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Other | 124 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 436 | $26K | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 482 | $30K | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 406 | $26K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 2,342 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 862 | $54K | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,860 | $117K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 1,165 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 193 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 80 | $0 | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 1,107 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 399 | $0 | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 6,641 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 2,449 | $0 | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 994 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 246 | $13K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 1,164 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 201 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 157 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 283 | $15K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 6,985 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 2,431 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,436 | $77K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 616 | $0 | 12/2/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 274 | $14K | 12/2/2023 | View on chart |
| BMY | ▼ Sell | Open Market | 732 | $45K | 8/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.